Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells - PubMed (original) (raw)

Comparative Study

Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells

Jamie D Croxtall et al. Br J Pharmacol. 2002 Jan.

Abstract

We have examined the effects of 12 glucocorticoids as inhibitors of A549 cell growth. Other than cortisone and prednisone, all the glucocorticoids inhibited cell growth and this was strongly correlated (r=0.91) with inhibition of prostaglandin (PG)E(2) formation. The molecular mechanism by which the active steroids prevented PGE(2) synthesis was examined and three groups were identified. Group A drugs did not inhibit arachidonic acid release but inhibited the induction of COX2. Group B drugs were not able to inhibit the induction of COX2 but inhibited arachidonic acid release through suppression of cPLA(2) activation. Group C drugs were apparently able to bring about both effects. The inhibitory actions of all steroids was dependent upon glucocorticoid receptor occupation since RU486 reversed their effects. However, group A acted through the NF-kappaB pathway to inhibit COX2 as the response was blocked by the inhibitor geldanamycin which prevents dissociation of GR and the effect was blocked by APDC, the NF-kappaB inhibitor. On the other hand, the group B drugs were not inhibited by NF-kappaB inhibitors or geldanamycin but their effect was abolished by the src inhibitor PP2. Group C drugs depended on both pathways. In terms of PGE(2) generation, there is clear evidence of two entirely separate mechanisms of glucocorticoid action, one of which correlates with NF-kappaB mediated genomic actions whilst the other, depends upon rapid effects on a cell signalling system which does not require dissociation of GR. The implications for these findings are discussed.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Representative examples of the effect of GCs from each group upon IL-1β activation of cPLA2 and induction of COX2 expression. A549 cells were treated with 1 ng ml−1 for 3 h in the presence of a range of concentrations of each GC (10−10–10−5

M

). Immunoprecipitates of cPLA2 were examined for activation status by Western blotting with antibodies to phosphoserine. COX2 expression was assessed by Western blotting the total cell lysate with COX2 antibody.

Similar articles

Cited by

References

    1. BARNES P.J. Therapeutic strategies for allergic diseases. Nature. 1999;402 Suppl.:B31–B38. - PubMed
    1. BARNES P.J. Optimizing the anti-inflammatory effects of corticosteroids. Eur. Respir. Rev. 2001;11:7815–7822.
    1. BARNES P., PEDERSEN S., BUSSE W.W. Efficacy and safety of inhaled corticosteroids: an update. Am. J. Respir. Crit. Care Med. 1998;157:S1–S53. - PubMed
    1. BATEMAN E.D., BRITTON M., CARRILLO J., ALMEIDA J., WIXON C. Salmeterol/fluticasone combination inhaler. A new, effective and well-tolerated treatment for asthma. Clin. Drug Invest. 1998;16:193–201. - PubMed
    1. BEATO M., HERRLICH P., SCHUTZ G. Steroid hormones receptors: many actors in search of a plot. Cell. 1995;83:851–857. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources